GenomeDx Biosciences, a US-based genomic information company that counts pharmaceutical company Merck & Co as an investor, has secured $25.4m in new funding, according to a securities filing.
The investors in the round were not disclosed but signatories to the filing included Lawrence Senour, managing director of Merck subsidiary Merck Global Health Innovation, as well as company directors representing Aeris Capital, Tekla Capital Management and Baird Capital.
GenomeDx is developing cancer diagnostics products, and released Decipher Biopsy, a genomic test for prostate cancer, last week. It has also built a genomic data sharing platform called Decipher Grid as an open and interactive research collaboration and knowledge project.
Merck Global Health Innovation led a series B round of unspecified size for GenomeDx in 2013, investing alongside Aeris, Baird and CD Ventures, the three investors that funded the company’s 2012 series A round, also of undisclosed size.
CRG subsequently provided GenomeDx with an undisclosed amount of debt financing in September 2015.